Doç. Dr. Heves Sürmeli

Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group Study

Clinical Medicine Insights Oncology, 2026

DOI 10.1177/11795549261445290 PMID 42131419 Open-access full textSource: OpenAlex

Prognostic value of PSA Kinetic Ratio in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study

BMC Cancer, 2026

DOI 10.1186/s12885-026-16037-8 PMID 41987096 Open-access full textSource: OpenAlex

Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide

Journal of Clinical Medicine, 2026

DOI 10.3390/jcm15010386 PMID 41517635 1 citation (Europe PMC) Open-access full textSource: OpenAlex

Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma

Journal of Cancer Research and Clinical Oncology, 2026

DOI 10.1007/s00432-025-06411-7 PMID 41504775 3 citations (Europe PMC) Open-access full textSource: OpenAlex

Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk–Stratified Analysis

Journal of Clinical Medicine, 2026

DOI 10.3390/jcm15051853 PMID 41827267 1 citation (Europe PMC) Open-access full textSource: OpenAlex

Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study

Medicina, 2026

DOI 10.3390/medicina62010099 PMID 41597386 1 citation (Europe PMC) Open-access full textSource: OpenAlex

Pan‑immune‑inflammation value as a prognostic and predictive biomarker in metastatic non‑small cell lung cancer treated with nivolumab: A real‑world study

Oncology Letters, 2026

DOI 10.3892/ol.2026.15750 PMID 42491228 Open-access full textSource: ORCID

Prognostic Value of the Cancer Inflammation Prognostic Index (CIPI) in De Novo Metastatic Colon Cancer: A Multicenter Retrospective Cohort Study

Cancer Control, 2026

DOI 10.1177/10732748261432273 PMID 41779425 Open-access full textSource: ORCID

Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer

The Oncologist, 2025

DOI 10.1093/oncolo/oyaf054 PMID 40271640 5 citations (Europe PMC) Open-access full textSource: OpenAlex

Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage

Journal of Clinical Medicine, 2025

DOI 10.3390/jcm14197103 PMID 41096183 4 citations (Europe PMC) Open-access full textSource: OpenAlex

Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study

Journal of Personalized Medicine, 2025

DOI 10.3390/jpm16010008 PMID 41590501 3 citations (Europe PMC) Open-access full textSource: OpenAlex

Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine

Medicina, 2025

DOI 10.3390/medicina61050819 PMID 40428777 1 citation (Europe PMC) Open-access full textSource: OpenAlex

Effects of Metformin on Survival and Toxicity in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab

Medicina, 2025

DOI 10.3390/medicina61071161 PMID 40731791 1 citation (Europe PMC) Open-access full textSource: OpenAlex

The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis

BMC Cancer, 2025

DOI 10.1186/s12885-025-14252-3 PMID 40329228 3 citations (Europe PMC) Open-access full textSource: OpenAlex

Impact of Age and Menopausal Status on T-DM1 (Ado-Trastuzumab Emtansine) Treatment Outcomes in HER2-Positive Breast Cancer

Pharmaceuticals, 2025

DOI 10.3390/ph18060931 PMID 40573326 1 citation (Europe PMC) Open-access full textSource: OpenAlex

Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy

Current Oncology, 2025

DOI 10.3390/curroncol32090503 PMID 41002573 1 citation (Europe PMC) Open-access full textSource: OpenAlex

Impact of Metastasectomy on Survival Outcomes in Colorectal Cancer: A Single Center Retrospective Study

Acta haematologica oncologica Turcica., 2025

DOI 10.4274/ahot.galenos.2025.2025-1-1 Open-access full textSource: OpenAlex

Very Favorable vs. Favorable Risk Groups in Metastatic Renal Cell Carcinoma: A Step Toward Personalized Treatment

Cancers, 2025

DOI 10.3390/cancers17071076 PMID 40227569 Open-access full textSource: OpenAlex

Effect of Family and Personal Medical History on Treatment Outcomes of Tyrosine Kinase Inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC)

Healthcare, 2025

DOI 10.3390/healthcare13151810 PMID 40805843 Open-access full textSource: OpenAlex

Association Between Prognostic Nutritional Index and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Cerrahpasa Medical Journal, 2025

DOI 10.5152/cjm.2025.25030 Open-access full textSource: OpenAlex

Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study

Medicina, 2025

DOI 10.3390/medicina61010154 PMID 39859134 2 citations (Europe PMC) Open-access full textSource: ORCID

The Effect of Concomitant Metformin Use on Progression-Free and Overall Survival in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab

2025

DOI 10.20944/preprints202506.0074.v1 Open-access full textSource: ORCID

The Potential Synergistic Effects of Metformin and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Southern Clinics of Istanbul Eurasia, 2025

DOI 10.14744/scie.2025.65768 Open-access full textSource: OpenAlex

Impact of Progression Sites and Line of Therapy on Survival Outcomes in Patients with Her-2 Positive Metastatic Breast Cancer Treated with T-DM1

Northern Clinics of Istanbul, 2025

DOI 10.14744/nci.2025.48902 PMID 41059432 Open-access full textSource: OpenAlex

EP.14.06 Survival Analysis in Malignant Pleural Mesothelioma

Journal of Thoracic Oncology, 2025

DOI 10.1016/j.jtho.2025.09.1650 Open-access full textSource: OpenAlex

The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy

Scientific Reports, 2024

DOI 10.1038/s41598-024-63096-7 PMID 38802494 21 citations (Europe PMC) Open-access full textSource: OpenAlex

Prognostic Impact and Clinical Features of Spread through Air Spaces in Operated Lung Cancer: Real-World Analysis

Medicina, 2024

DOI 10.3390/medicina60081374 PMID 39202654 10 citations (Europe PMC) Open-access full textSource: OpenAlex

A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients

Cancers, 2024

DOI 10.3390/cancers16142512 PMID 39061152 5 citations (Europe PMC) Open-access full textSource: OpenAlex

Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older

Journal of Clinical Medicine, 2024

DOI 10.3390/jcm13206263 PMID 39458213 2 citations (Europe PMC) Open-access full textSource: OpenAlex

Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer?

Medicina, 2024

DOI 10.3390/medicina60081372 PMID 39202652 3 citations (Europe PMC) Open-access full textSource: OpenAlex

Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-World Study

Medicina, 2024

DOI 10.3390/medicina60071088 PMID 39064516 1 citation (Europe PMC) Open-access full textSource: OpenAlex

Trastuzumab Rechallenge in HER2-Positive Metastatic Breast Cancer: A Promising Strategy for Enhanced Progression-Free Survival Post Ado-Trastuzumab Emtansine Progression

Medicina, 2024

DOI 10.3390/medicina60122069 PMID 39768949 2 citations (Europe PMC) Open-access full textSource: OpenAlex

Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy

Cureus, 2024

DOI 10.7759/cureus.63362 PMID 39070363 1 citation (Europe PMC) Open-access full textSource: OpenAlex

Association of New Inflammatory Markers Cumulative Inflammatory Index (ICC) and Mean Corpuscular Volume/Lymphocyte (MCVL) with Anti PD-1 Antibody Nivolumab Treatment Response in Metastatic Renal Cell Carcinoma

Research Square, 2024

DOI 10.21203/rs.3.rs-5381728/v1 Open-access full textSource: OpenAlex

Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older

2024

DOI 10.20944/preprints202409.0812.v1 Open-access full textSource: ORCID

Outcomes of surveillance versus adjuvant treatment for patients with stage-I seminoma: a single-center experience

World journal of urology, 2023

DOI 10.1007/s00345-023-04482-0 PMID 37351618 3 citations (Europe PMC) Source: Europe PMC

Sarkomlar ve Cilt Tümörleri

Akademisyen Kitabevi eBooks, 2022

DOI 10.37609/akya.1097 Open-access full textSource: OpenAlex

Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer?

Journal of Oncology Pharmacy Practice, 2021

DOI 10.1177/10781552211015762 PMID 33961521 10 citations (Europe PMC) Open-access full textSource: OpenAlex

Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient?

Journal of Oncology Pharmacy Practice, 2021

DOI 10.1177/10781552211038136 PMID 34558355 1 citation (Europe PMC) Source: OpenAlex

Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer

Journal of Oncology Pharmacy Practice, 2021

DOI 10.1177/1078155220924088 PMID 32423326 8 citations (Europe PMC) Source: ORCID

Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?

Current Problems in Cancer, 2020

DOI 10.1016/j.currproblcancer.2020.100670 PMID 33129567 1 citation (Europe PMC) Source: OpenAlex

Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer

Turkish journal of obstetrics and gynecology, 2020

DOI 10.4274/tjod.galenos.2020.90699 PMID 32850187 2 citations (Europe PMC) Open-access full textSource: Europe PMC

Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients

Tumor Biology, 2016

DOI 10.1007/s13277-015-4776-1 PMID 26753955 11 citations (Europe PMC) Source: OpenAlex

Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma

Clinical Colorectal Cancer, 2016

DOI 10.1016/j.clcc.2016.04.013 PMID 27247089 17 citations (Europe PMC) Source: OpenAlex

Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy

Clinical & Translational Oncology, 2015

DOI 10.1007/s12094-015-1283-1 PMID 25786367 23 citations (OpenAlex) Source: OpenAlex

The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients

Clinical & Translational Oncology, 2015

DOI 10.1007/s12094-015-1408-6 PMID 26459249 3 citations (OpenAlex) Source: OpenAlex

Three Different Chemotherapy Combinations with Concurrent Thoracic Radiation for Patients with Stage III Non-Small Cell Lung Cancer

Annals of Oncology, 2014

DOI 10.1093/annonc/mdu348.10 Open-access full textSource: OpenAlex

Approach to mushroom intoxication and treatment: Can we decrease mortality?

Clinics and Research in Hepatology and Gastroenterology, 2011

DOI 10.1016/j.clinre.2011.11.004 PMID 22189510 33 citations (OpenAlex) Source: OpenAlex